Multiple Myeloma News

CancerConnect multiple myeloma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of multiple myeloma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of multiple myeloma treatment and survivorship.

Share

Multiple Myeloma News


Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (March 22, 2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival... Continue Reading

March is Multiple Myeloma Awareness Month: Learn About Recent Advances (March 21, 2017)

There are several recent advances of note in the management of all stages of Multiple Myeloma. Smoldering myeloma is considered to be a pre-cancerous condition, in which patients do not yet display any... Continue Reading

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were... Continue Reading

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma... Continue Reading

Scientific Highlights from American Society of Hematology Meeting (January 24, 2017)

About CAR-T CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant multiple... Continue Reading

Useful Definitions and Diagnostic Tests (January 23, 2017)

Diagnostic testing for multiple myeloma utilizes unique blood, urine, and bone marrow tests in addition to a variety of standard medical tests. Cancer Connect provides comprehensive information on Blood... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA... Continue Reading

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma (October 12, 2016)

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed... Continue Reading

Advances offer Promise for Multiple Myeloma Patients (September 1, 2016)

With a growing number of treatment options, the out­look is improving for patients with this blood cancer. By Mia James Una Wilson initially thought that the early signs of multiple my­eloma (MM) were... Continue Reading

More Multiple Myeloma News

Latest Multiple Myeloma News By Stage


Stage I/Smoldering Myeloma

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective of PCROWD is to collect, process, store and study... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate the economic “value” of newly approved therapies... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity to engage with a multiple myeloma expert, Craig... Continue Reading

Have a Question about Multiple Myeloma? Join us on April 28th (April 26, 2016)

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect in collaboration with The Ohio State University Comprehensive... Continue Reading

More Stage I/Smoldering Myeloma

Stages II-III

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate the economic “value” of newly approved therapies... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity to engage with a multiple myeloma expert, Craig... Continue Reading

More Stages II and III

Recurrent

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate the economic “value” of newly approved therapies... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity to engage with a multiple myeloma expert, Craig... Continue Reading

Have a Question about Multiple Myeloma? Join us on April 28th (April 26, 2016)

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect in collaboration with The Ohio State University Comprehensive... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS